REGN Q2 2021 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5.1B+163.2% YoY

Gross Profit

$4.4B85.1% margin

Operating Income

$3.3B65.1% margin

Net Income

$3.1B60.3% margin

EPS (Diluted)

$27.97

QoQ Revenue Growth

+103.2%

Cash Flow

Operating Cash Flow

$627M

Free Cash Flow

$478M

Stock-Based Comp.

$146M

Balance Sheet

Total Assets

$21.5B

Total Liabilities

$6.4B

Stockholders' Equity

$15.1B

Cash & Equivalents

$2.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.1B	$2.0B	+163.2%
Gross Profit	$4.4B	$1.6B	+170.4%
Operating Income	$3.3B	$656M	+409.9%
Net Income	$3.1B	$897M	+245.4%

Revenue Segments

Product

$4.1B81%

Collaboration Revenue

$955M19%

Product and Service, Other

$46M1%